A new scoring system for predicting the outcome of hepatocellular carcinoma patients without microvascular invasion-a large-scale multicentre study
HPB · 2024
DOI: 10.1016/j.hpb.2024.02.007 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift HPB, 2024. Verfasst von Ju-Xian Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery VI, Third Affiliated Hospital of Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatectomy, Predictive Value of Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: The prognosis of HCC patients without MVI (so called M0) is highly heterogeneous and the need for adjuvant therapy is still controversial. METHODS: Patients with HCC with M0 who underwent liver resection (LR) or liver transplantation (LT) as an initial therapy were included. The Eastern Hepatobiliary Surgery Hospital (EHBH)-M0 score was developed from a retrospective cohort to form the training cohort. The classification which was developed using multivariate cox regression analysis was externally validated. RESULTS: The score was developed using the following factors: α-fetoprotein level, tumour diameter, liver cirrhosis, total bilirubin, albumin and aspartate aminotransferase. The score differentiated two groups of M0 patients (≤3, >3 points) with distinct long-term prognoses outcomes (median overall survival (OS), 98.0 vs. 46.0 months; p < 0.001). The predictive accuracy of the score was greater than the other commonly used staging systems for HCC. And for M0 patients with a higher score underwent LR. Adjuvant transcatheter arterial chemoembolization (TACE) was effective to prolong OS. CONCLUSIONS: The EHBH M0 scoring system was more accurate in predicting the prognosis of HCC patients with M0 after LR or LT. Adjuvant therapy is recommended for HCC patients who have a higher score.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Hepatic Surgery VI, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
- Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
- Department of Hepatobiliary Surgery, Fujian Provincial Hospital, the Shengli Clinical Medical College of Fujian Medical University, Fujian, China.
- Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China. Electronic address: yanmaolin74@163.com.
- Department of Hepatic Surgery VI, Third Affiliated Hospital of Naval Medical University, Shanghai, China. Electronic address: chengshuqun@aliyun.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, J. X., Yang, Z., Wu, J. Y., Shi, J., Yu, H. M., Yan, M. L., Zheng, S. S., & Cheng, S. Q. (2024). A new scoring system for predicting the outcome of hepatocellular carcinoma patients without microvascular invasion-a large-scale multicentre study. HPB. https://doi.org/10.1016/j.hpb.2024.02.007
Vancouver
Sun JX, Yang Z, Wu JY, Shi J, Yu HM, Yan ML, et al. A new scoring system for predicting the outcome of hepatocellular carcinoma patients without microvascular invasion-a large-scale multicentre study. HPB. 2024. doi:10.1016/j.hpb.2024.02.007
BibTeX
@article{Sun2024,
author = {Sun, Ju-Xian and Yang, Zhe and Wu, Jia-Yi and Shi, Jie and Yu, Hong-Ming and Yan, Mao-Lin and Zheng, Shu-Sen and Cheng, Shu-Qun},
title = {A new scoring system for predicting the outcome of hepatocellular carcinoma patients without microvascular invasion-a large-scale multicentre study},
journal = {HPB},
year = {2024},
doi = {10.1016/j.hpb.2024.02.007}
}
EUVIMED